DMDG past Open and Joint meeting programmes

Joint Meeting 2016
- in partnership with the GMP (Groupe de Métabolisme et Pharmacocinétique)

19 - 21 October 2016 - Paris, France

Wednesday 19th October 2016

11.00-12.00 **Arrival, Registration & Lunch**

13.00-13.30 **Chairs' Opening Address**
Suzanne Iverson Hemberg, Sahlgrenska University Hospital, Sweden
Vassilios Aslanis, Novartis, Switzerland

13.30-14.30 **Keynote Speaker**
Spatially resolved assessment of drug-induced changes in metabolism by mass spectrometric imaging
Prof Zoltan Takats, Ph.D, Imperial College London, UK

14.30-15.00 **Tea and coffee**

15.00-17.00 **Session 1 – The impact of pre-clinical PKPD modelling on drug discovery and development**
Chairs. James Yates and Marc Trellu
Speakers.

1.1 Application of model based drug discovery from target idea to early clinical studies – a case study
Rasmus Jansson Löfmark,. AstraZeneca R&D Mölndal, Sweden

1.2 Drug profiling in discovery using model based approach to project from in vitro to patients
Caterina Bissantz , Roche, Switzerland

1.3 How early ePKPD may help the drug discovery process? Specific examples and case studies will be highlighted to help demonstrate key points for opportunities and benefits
Pierre-Yves Abecassis, Sanofi R&D, France

17.00-17.30 **Poster Blitz** - 5-minute presentations from selected posters to engage audience prior to the poster session

17.30-19.00 **Poster Session**
Wine and food available
Organisers. Peter Kilford, Florence Gattacceca and Sunil Mathur

19.00 **End of session**

Thursday 20th October 2016

09.00-10.30 **Session 2 – Implementing biodistribution to better understand PK**
Chairs. Sherri Dudal; Graeme Clark and Florence Gattacceca
Speakers.

2.1 Hunt for off-target binding - biodistribution and in vitro attempts to solve atypical PK
Kevin Brady, F. Hoffman-La Roche, Switzerland

2.2 Mass spectrometry imaging applied to investigating drug efficacy and toxicity across pharmaceutical R&D
Richard Goodwin, AstraZeneca, UK

2.3 Optimising PK of therapeutics using Veltis®-albumin-based technologies – from rational design to PK/PD and biodistribution
Jenny McLaughlan, Albumedix (formerly Novozymes), UK

2.4 Ocular Drug Distribution. Impact of Melanin Binding
Arto Urtti, University of Helsinki, Finland

10.30-10.50 **Coffee**

10.50-12.20 **Session 3 – Skin Metabolism**
Chairs. Vibeke Hougaard Sunesen and André Huss Eriksson

Speakers.

3.1 Drug metabolism in the skin. Relevance for development of dermally applied drug products
Clemens Günther, Bayer, Germany

3.2 Skin Metabolism. Comparison of In Vitro Methods and Models
Carine Jacques-Jamin, Pierre-Fabre, France

3.3 *In Vitro* Measurements to Determine Cutaneous Bioavailability
Joan Eilstein, L'Oréal, France

3.4 Contribution of dermal metabolism to local toxicities
Simon Wilkinson, University of Newcastle, UK

12.20-13.50 **Lunch**

13.50-15.20 **Session 4 – New Approaches for the Prediction of ADME Parameters**
Chairs. Angus Nedderman and Marion Millet
Speakers.

4.1 Direct and quantitative evaluation of the human CYP450 contribution (fm) to drug clearance using the in vitro SILENSOMES™ model
Yannick Parmentier, Servier, France

4.2 Upcyte® Human Hepatocytes – Application for clearance prediction of metabolically stable compounds
Michelle Schaefer, Boehringer Pharma, Germany

4.3 Computational prediction of sites of metabolism
Prof Robert Glen, Imperial College London, UK

15.20-15.40 **Tea and coffee**

15.40-17.10 **Session 5 – Bioanalysis of Biomarkers. Challenges, pitfalls and new perspectives**
Chairs. Karelle Menochet & Tim Sangster
Speakers.

5.1 Biomarker strategy and bioanalytical challenges for biologics in preclinical drug discovery and development for use in PKPD
Sherri Dudal, UCB, UK

5.2 Biomarker assay validation in practice. EBF Recommendation in practice and feedback from the recent EBF Focus Workshop (June, Lisbon)
Marianne Scheel Fjording, NovoNordisk, Denmark and Philip Timmerman, Janssen R&D, Belgium

5.3 Bioanalysis of miRNAs. The Same but Different
Keith Sutton, Charles River Laboratories, UK

17.10-18.00 **Keynote Speaker**
The TeGenero and Bial trials - the importance of pharmacology for taking medicines safely into humans
Michael Eddleston, University of Edinburgh, UK

18.00 **End of session**

19.30 **Conference Dinner & Entertainment**

Friday 21st October 2016

09.00-10.30 **Session 6 - The impact of Transporters in drug discovery. its not just about small molecules**
Chair. Mohammed Ullah
Speakers.

6.1 Transporter strategy in drug discovery and development. Understanding the impact of active transport on human pharmacokinetics
Karelle Menochet, UCB, UK

6.2 Cross-membrane transport of NBEs. a cell-based approach to study impact of FcRn recycling in vitro and its correlation with in vivo clearance
Silke Simon, Roche, Switzerland

6.3 Assessment of Antisense Oligonucleotide Disposition in cells
Erich Koller, Roche, Switzerland

10.30-10.50 **Tea and coffee**

10.50-12.30 **Session 7 – PBPK application in clinical development to support regulatory submission**
Chairs. Antoine Deslandes and Sylvaine Cartot-Cotton
Speakers.

7.1 A Case of Regulatory Acceptance of a PBPK Modelling Approach to Answer Key Drug-Drug Interaction Questions
Venkatesh Pilla Reddy, AstraZeneca, UK

7.2 Physiologically-based pharmacokinetic modeling for prediction of drug-drug interactions. Eliglustat (Cerdelga®) as a case study
Vanaja Kanamaluru, Sanofi R&D, USA

7.3 PBPK, a tool for designing better clinical trials – application to pediatric studies
Marylore Chenel, Servier, France

12.30-13.00 **Closing Remarks**

13.00 **Lunch and Delegates Depart**